Demis Hassabis Raises $2.1B for Isomorphic Labs - AlphaFold's Next Mission Is Curing Disease

Isomorphic Labs has secured $2.1 billion in funding, with CEO Demis Hassabis positioning the round as crucial acceleration for the company's ambitious goal of solving all disease. The DeepMind spinout, built on the Nobel Prize-winning AlphaFold protein structure prediction model, has attracted investment led by Thrive Capital alongside parent company Alphabet. The substantial funding round significantly exceeds the $600 million Isomorphic raised in 2025, providing the company with extended runway as it navigates the lengthy drug development process. Hassabis has adjusted timelines, pushing the company's first human trials from late 2025 to the end of 2026, with oncology candidates taking priority in the development pipeline. The company's existing partnerships with pharmaceutical giants Novartis and Eli Lilly represent potential milestone payments approaching $3 billion, though these are contingent on successful patient outcomes. The next eighteen months will prove critical in determining whether AlphaFold's laboratory successes can translate into viable clinical treatments. This funding represents the largest single investment in AI-designed medicine to date, signalling significant confidence in computational drug discovery. Success could fundamentally disrupt traditional pharmaceutical development processes, whilst failure would raise questions about the current timeline for AI's impact on drug discovery.